{"id":"tegafur-uracil-folinic-acid","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL235993","moleculeType":"Small molecule","molecularWeight":"200.17"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Tegafur is converted to 5-fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and disrupts DNA synthesis. Folinic acid potentiates the effect of 5-FU by enhancing its conversion to its active metabolites and reducing its degradation.","oneSentence":"Tegafur uracil combined with folinic acid enhances the cytotoxic effects of 5-fluorouracil by increasing its intracellular concentration and prolonging its action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:47.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced colorectal cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT00905047","phase":"PHASE3","title":"Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2005-11-14","conditions":"Colorectal Cancer","enrollment":89},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT03406299","phase":"PHASE2","title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-19","conditions":"Biliary Tract Neoplasms","enrollment":92},{"nctId":"NCT06662877","phase":"PHASE2, PHASE3","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-25","conditions":"Biliary Tract Cancer, Second Line Treatment, Chemotherapy","enrollment":206},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":"Efficacy and Safety","enrollment":120},{"nctId":"NCT00004860","phase":"PHASE2","title":"Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2000-10-09","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT05774964","phase":"PHASE2","title":"Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-15","conditions":"For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method","enrollment":100},{"nctId":"NCT03162510","phase":"PHASE1","title":"Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-06-26","conditions":"Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers","enrollment":18},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT02836977","phase":"NA","title":"Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-03","conditions":"Stage III Colon Cancer","enrollment":400},{"nctId":"NCT01050426","phase":"PHASE2","title":"A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2009-03","conditions":"Pancreatic Cancer","enrollment":17},{"nctId":"NCT00660894","phase":"PHASE3","title":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2008-04","conditions":"Colorectal Cancer","enrollment":1535},{"nctId":"NCT02817425","phase":"PHASE2, PHASE3","title":"A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2013-05","conditions":"Gastric Cancer","enrollment":300},{"nctId":"NCT00439517","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2007-02","conditions":"Previously Untreated Metastatic Colorectal Cancer","enrollment":302},{"nctId":"NCT01225744","phase":"PHASE2","title":"Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2009-04","conditions":"Metastatic Colorectal Cancer","enrollment":47},{"nctId":"NCT02090153","phase":"PHASE2","title":"Study of S-1 Plus LV for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-07","conditions":"Gastric Cancer","enrollment":39},{"nctId":"NCT00002801","phase":"PHASE1","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1996-04","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT00009815","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"1999-12","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00009828","phase":"PHASE1","title":"Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"1999-12","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00003925","phase":"PHASE1","title":"Combination Chemotherapy In Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"1998-05","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":36},{"nctId":"NCT00385970","phase":"PHASE3","title":"A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer","status":"UNKNOWN","sponsor":"Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group","startDate":"2006-03","conditions":"Colorectal Cancer","enrollment":380},{"nctId":"NCT00005608","phase":"PHASE2","title":"Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2000-02","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00209742","phase":"PHASE3","title":"Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer","status":"UNKNOWN","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2005-04","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT00378716","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Resected Colon Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"1997-02","conditions":"Colorectal Cancer","enrollment":1608},{"nctId":"NCT00677612","phase":"PHASE1, PHASE2","title":"Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"Tokyo University","startDate":"2008-05","conditions":"Colorectal Cancer, Colon Cancer, Rectal Cancer","enrollment":14},{"nctId":"NCT00677287","phase":"PHASE1, PHASE2","title":"Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"Tokyo University","startDate":"2008-05","conditions":"Colorectal Cancer, Colon Cancer, Rectal Cancer","enrollment":14},{"nctId":"NCT00497107","phase":"PHASE3","title":"Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer","status":"UNKNOWN","sponsor":"Iwate Medical University","startDate":"2007-07","conditions":"Colorectal Cancer","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TEGAFUR URACIL - FOLINIC ACID","genericName":"TEGAFUR URACIL - FOLINIC ACID","companyName":"Centre Oscar Lambret","companyId":"centre-oscar-lambret","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tegafur uracil combined with folinic acid enhances the cytotoxic effects of 5-fluorouracil by increasing its intracellular concentration and prolonging its action. Used for Advanced colorectal cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}